NeuroOne® to Present at HC Wainwright’s 26th Annual Global Investment Conference

EDEN PRAIRIE, Minn., Sept. 5, 2024 (GLOBE NEWSWIRE) — NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and patient outcomes for neurological disorders, today announced its upcoming virtual investor presentation at the 26th Annual HC Wainwright Global Investment Conference, to be held in person and virtually September 9-11, 2024.

The company’s virtual presentation by Chief Operating Officer Chris Volker will be available on-demand from 7:00 a.m. ET on Monday, September 9, 2024 through the end of the conference call. Investors can register for the conference call to access the presentation Here. One-on-one meetings are available to registered investors via the conference website or by contacting your HC Wainwright representative.

About NeuroOne

NeuroOne Medical Technologies Corporation is a development-stage company focused on providing minimally invasive, high-resolution EEG, brain stimulation, and ablation solutions for patients with epilepsy, Parkinson’s disease, dystonia, essential tremor, chronic pain from failed spinal surgeries, and other related neurological disorders that can improve patient outcomes and reduce procedural costs. The company is also seeking applications in other areas, such as depression, mood disorders, pain, urinary incontinence, high blood pressure, and artificial intelligence. For more information, visit www.nmtc1.com.

Forecast statements

This press release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Except for statements of historical fact, any information contained in this press release may be forward-looking statements that reflect NeuroOne’s current views with respect to future events and are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from those expressed or implied by these forward-looking statements. In some cases, you can identify forward-looking statements by the words or phrases “may,” “might,” “will,” “could,” “should,” “expect,” “intend,” “plan,” “goal,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “target,” “seek,” “consider,” “continue,” “focused on,” “committed to,” and “continuing” or the negative of these terms or other comparable terminology intended to identify forward-looking statements. Forward-looking statements may include statements regarding the transition of manufacturing from sEEG diagnostic leads to OneRF leads, the addition of new centers as part of the Company’s limited commercial launch, potential strategic partnership opportunities, the continued development of the Company’s lead technology program (including our drug delivery program and spinal cord stimulation program), business strategy, market size, potential growth opportunities, future operations, future performance, and other financial and operating information. Although NeuroOne believes that we have a reasonable basis for each forward-looking statement, we caution you that these statements are based on a combination of facts and factors currently known to us and our expectations regarding the future, about which we cannot be certain. Our actual future results may differ materially from those we expect due to factors largely beyond our control, including the risk that the partnership with Zimmer Biomet may not facilitate the commercialization or market acceptance of our technology; whether due to supply chain disruptions, labor shortages or other reasons; the risk that our technology will not perform as expected based on the results of our preclinical and clinical studies; risks related to uncertainties related to the Company’s capital requirements to achieve its business objectives and the ability to obtain additional funds: the risk that we will be unable to secure or maintain coverage or adequate reimbursement for the costs of our technology; uncertainties inherent in the development of our technology; risks related to changes in regulatory requirements or decisions by regulatory authorities; that we may not have accurately estimated the size and growth potential of the markets for our technology; risks related to patient recruitment in clinical trials and clinical trial results; that we may not be able to protect our intellectual property rights; and other risks, uncertainties and assumptions, including those described in the “Risk Factors” section of our filings with the Securities and Exchange Commission. These forward-looking statements speak only as of the date of this press release, and NeuroOne undertakes no obligation to revise or update any forward-looking statements for any reason, even if new information becomes available in the future.

“Caution: Federal law restricts this device to sale by or on the order of a physician”

Contact:
800-631-4030
[email protected]